Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
Trial record 5 of 6 for:    bacterial vaginosis | NICHD | NIH

BufferGel and PRO 2000/5: Vaginal Gels to Prevent HIV Infection in Women

This study has been completed.
Sponsor:
Collaborators:
HIV Prevention Trials Network
Information provided by (Responsible Party):
National Institute of Allergy and Infectious Diseases (NIAID)
ClinicalTrials.gov Identifier:
NCT00074425
First received: December 11, 2003
Last updated: July 5, 2013
Last verified: July 2013
  Purpose

The majority of HIV infected people worldwide became infected with the virus through heterosexual contact. BufferGel and PRO 2000 Gel are vaginal gels designed to prevent women from becoming infected with HIV during sexual intercourse with an HIV infected partner. This study will test the safety and effectiveness of these gels.


Condition Intervention Phase
HIV Infections
Drug: BufferGel
Drug: PRO 2000/5 Gel
Drug: Placebo gel
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Factorial Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: Phase II/IIb Safety and Effectiveness Study of the Vaginal Microbicides BufferGel and 0.5% PRO 2000/5 Gel (P) for the Prevention of HIV Infection in Women

Resource links provided by NLM:


Further study details as provided by National Institute of Allergy and Infectious Diseases (NIAID):

Primary Outcome Measures:
  • Safety of BufferGel and 0.5% PRO 2000/5 Gel (P), as assessed by deep epithelial disruption, other genital symptoms, or other systemic symptoms [ Time Frame: Throughout study ] [ Designated as safety issue: Yes ]
  • HIV infection as measured by seroconversion [ Time Frame: Throughout study ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Bacterial vaginosis [ Time Frame: Throughout study ] [ Designated as safety issue: No ]
  • Chlamydia infection [ Time Frame: Throughout study ] [ Designated as safety issue: No ]
  • Genital ulcer disease [ Time Frame: Throughout study ] [ Designated as safety issue: No ]
  • Gonorrhea infection [ Time Frame: Throughout study ] [ Designated as safety issue: No ]
  • Herpes simplex virus-2 infection [ Time Frame: Throughout study ] [ Designated as safety issue: No ]
  • Pregnancy [ Time Frame: Throughout study ] [ Designated as safety issue: No ]
  • Syphilis infection [ Time Frame: Throughout study ] [ Designated as safety issue: No ]
  • Trichomoniasis [ Time Frame: Throughout study ] [ Designated as safety issue: No ]
  • Acceptability of study product [ Time Frame: At Month 3 and study exit ] [ Designated as safety issue: No ]
  • Number of behavioral risk assessment questions not answered in self-reported interviews [ Time Frame: Throughout study ] [ Designated as safety issue: No ]
  • Rates of condom use versus gel use [ Time Frame: Throughout study ] [ Designated as safety issue: No ]
  • Establishment of a repository of vaginal swab specimens for long-term storage and future research testing on biomarkers of microbicide safety and effectiveness [ Time Frame: Throughout study ] [ Designated as safety issue: No ]

Enrollment: 3101
Study Start Date: January 2005
Study Completion Date: September 2008
Primary Completion Date: September 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
BufferGel
Drug: BufferGel
Participants will be given single-use, prefilled applicators of gel and will be instructed to apply one dose of BufferGel intravaginally up to 60 minutes before each vaginal intercourse while in the study.
Experimental: 2
Pro 2000/5 Gel (P)
Drug: PRO 2000/5 Gel
Participants will be given single-use, prefilled applicators of gel and will be instructed to apply one dose of PRO 2000/5 Gel intravaginally up to 60 minutes before each vaginal intercourse while in the study.
Placebo Comparator: 3
Placeo Gel
Drug: Placebo gel
Participants will be given single-use, prefilled applicators of gel and will be instructed to apply one dose of PRO 2000/5 Gel intravaginally up to 60 minutes before each vaginal intercourse while in the study.
No Intervention: 4

Detailed Description:

Accessible, usable, and effective vaginal microbicides could significantly decrease the spread of HIV. Vaginal microbicides could be used with condoms to prevent HIV infection; they could also be used in situations in which an individual is unable to negotiate condom use. Vaginal microbicides are potentially bidirectional, preventing both male-to-female and female-to-male HIV transmission. This study will evaluate the safety and effectiveness of two vaginal microbicides, BufferGel and PRO 2000/5, in preventing the transmission of HIV. The study will also evaluate the effectiveness of these gels in preventing other common sexually transmitted infections (STIs).

BufferGel is a buffering agent designed to maintain normal vaginal acidity in the presence of ejaculate. Studies have shown that HIV is inactivated below a pH of 4 to 5.8. Carbopol 974, the major nonaqueous component of BufferGel, is commonly used as a gelling or tableting agent and has a well-documented safety record. BufferGel has proven safe and well tolerated in Phase I studies. PRO 2000/5 inhibits viral entry into susceptible cells. PRO 2000/5 has also been evaluated in Phase I studies and was found to be safe and well tolerated.

Participants in this study will be randomly assigned to receive one of four interventions: BufferGel, PRO 2000/5, placebo gel, or no gel. All participants will receive HIV risk reduction counseling, condoms, and diagnosis and treatment of sexually transmitted diseases. Participants in the three gel arms will be given single-use, prefilled applicators of gel and will be instructed to apply one dose of the product (BufferGel, PRO 2000/5, or placebo gel) intravaginally up to 60 minutes before each vaginal intercourse while in the study.

Participants will be enrolled for approximately 12 to 30 months, depending on when they enter the study. Participants will have two screening study visits and then monthly visits. Monthly study visits may take place at a clinic, the participant's home, or other community site. Monthly visits will include a medical interview; urine testing, including pregnancy testing; HIV and sexually transmitted infection risk reduction counseling; and distribution of study supplies (condoms and gel-filled applicators). Blood collection will occur at selected monthly visits. Four times a year, participants will be seen in the clinic for a more structured medical interview, pelvic exam, and HIV testing. At one of these visits, participants at particular sites who are willing will be asked to complete a behavioral risk assessment. At some visits vaginal fluid swabs will occur. Participants at non-US study sites will be asked for permission for these swabs to be stored for further testing. Assessment interviews will be both face to face and self-reporting.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Criteria

Note: Per the 12/15/06 amendment, all study participants will now enter the Phase IIb study.

Inclusion Criteria:

  • HIV uninfected
  • Have had sexual intercourse at least once in the 3 months prior to study entry
  • Able to provide adequate contact information to study officials for purposes of follow-up

Exclusion Criteria:

  • History of adverse reaction to latex
  • Nonmedical injection drug use in the 12 months prior to study entry
  • Vaginal intercourse more than an average of two times per day in the 2 weeks prior to study entry
  • Plan to become pregnant in the 30 months after study entry
  • Plan to travel away from the study site for more than 3 consecutive months in the 30 months after study entry
  • Plan to relocate away from the study site in the 30 months after study entry
  • Participation in another clinical trial of a vaginal product
  • Pregnant within 42 days of study entry
  • Have a sexually transmitted disease or other reproductive tract infection diagnosed by study staff
  • Abnormal pelvic exam indicating deep epithelial disruption
  • Condition that, in the opinion of the investigator, may interfere with the study
  • Liver or kidney function abnormality of Grade 3 or higher
  • Blood or blood clotting abnormality of Grade 4 or higher
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00074425

Locations
United States, Pennsylvania
3535 Market Street CRS
Philadelphia, Pennsylvania, United States
Malawi
University of North Carolina Lilongwe CRS
Lilongwe, Central, Malawi
College of Med. JHU CRS
Blantyre, Southern, Malawi
South Africa
Chatsworth CRS
Chatsworth, KwaZulu-Natal, South Africa
Med. Research Council-Hlabisa
Durban, KwaZulu-Natal, South Africa
Zambia
Kamwala Clinic CRS
Lusaka, Zambia
Zimbabwe
Seke South CRS
Chitungwiza, Zimbabwe, 263
Spilhaus CRS
Harare, Zimbabwe, 263
Sponsors and Collaborators
HIV Prevention Trials Network
Investigators
Study Chair: Salim Abdool Karim, MBChB, PhD University of KwaZulu-Natal, Centre for the AIDS Programme of Research in South Africa, Doris Duke Medical Research Institute, Nelson R. Mandela School of Medicine
Study Chair: Irving Hoffman, PA, MPH School of Medicine, University of North Carolina
Study Chair: Lisa Maslankowski, MD University of Pennsylvania
Study Chair: Groesbeck Parham, MD Centre for Infectious Disease Research in Zambia
Study Chair: Nancy Padian, PhD Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California, San Francisco; AIDS Research Institute
Study Chair: Gita Ramjee, PhD Medical Research Council, HIV Prevention Research Unit
Study Chair: Taha Taha, MD Johns Hopkins Bloomberg School of Public Health
  More Information

Additional Information:
Publications:

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: National Institute of Allergy and Infectious Diseases (NIAID)
ClinicalTrials.gov Identifier: NCT00074425     History of Changes
Obsolete Identifiers: NCT00197665
Other Study ID Numbers: HPTN 035, 10065
Study First Received: December 11, 2003
Last Updated: July 5, 2013
Health Authority: United States: Food and Drug Administration

Keywords provided by National Institute of Allergy and Infectious Diseases (NIAID):
HIV Seronegativity
Anti-Infective Agents, Local
BufferGel
PRO 2000
Vagina
Risk Factors

Additional relevant MeSH terms:
Acquired Immunodeficiency Syndrome
Communicable Diseases
HIV Infections
Infection
Immune System Diseases
Immunologic Deficiency Syndromes
Lentivirus Infections
RNA Virus Infections
Retroviridae Infections
Sexually Transmitted Diseases
Sexually Transmitted Diseases, Viral
Slow Virus Diseases
Virus Diseases

ClinicalTrials.gov processed this record on November 27, 2014